Remote Prescribing Restrictions: A Deeply Flawed Consultation That Demands Review

In recent months, the aesthetics industry has experienced a sharp and unexpected shift: the Nursing and Midwifery Council (NMC) has introduced a restriction requiring face-to-face consultations for the prescription of botulinum toxin and other injectable cosmetic aesthetic treatments.

This change followed a series of roundtable meetings that, despite being presented as informal information-gathering exercises, ultimately served as the foundation for a policy with profound implications. The process has been confusing, evoking fear and delivering significant operational challenges across the aesthetics sector, particularly for Independent Aesthetic Professionals, who comprise over 50% of the workforce, and for clients who rely on their services.

JCCP Lobbying and a Pre-Determined Outcome

Evidence shows that the Joint Council for Cosmetic Practitioners (JCCP) has been lobbying the NMC since 2019 to restrict remote prescribing in the aesthetic space. This campaign is recorded in JCCP’s public minutes. If the concerns raised had genuinely centred around safety, such a restriction would have been implemented sooner. Instead, it was delayed for years and pushed through rapidly with minimal engagement, once again raising questions about the true motive.

Targeting Cosmetic Treatments, But Not Healthcare

Remote prescribing continues to operate in other areas of healthcare, including for high-risk systemic medications like weight loss injections, with no additional restrictions. Yet it is elective cosmetic procedures, such as wrinkle-relaxing treatments, that have been singled out for criticism. These are temporary, non-surgical procedures for consenting adults with an excellent safety record based on insurance and MHRA regulatory data.

What the Data Shows

Injectable treatments in aesthetics, particularly botulinum toxin, have consistently shown low complication rates across millions of treatments.

This is backed by:

Years of insurer claims data.
Reports from the MHRA
A national survey conducted by Faces Pharmacy involving over 2,000 professionals, 85% of whom supported the continuation of remote prescribing

The Founders of Faces Pharmacy have confirmed that this data was submitted to the NMC and ultimately dismissed without explanation, confirming a troubling lack of transparency in the final decision-making process.

The Flaws in the NMC’s Consultation Process

The consultation itself was problematic in several key areas:

False framing: The NMC claimed this was not a formal consultation but an “informal roundtable.” Despite this, the resulting policy was implemented seven months later with only one month’s notice.
No clear justification: The rationale provided by the NMC (in a PDF deck shared post-meeting) cited general concerns like “lack of direct contact” and “pockets of poor practice” but included no supporting evidence or data.
Contradicts Government Digital Health Policy – The NMC cited a “rising trend of remote prescribing” as a concern, yet this directly conflicts with Health Secretary Wes Streeting’s endorsement of a digital-first NHS, where remote access and prescribing are actively encouraged across wider healthcare.
Selective exclusion: We know that Independent Aesthetic Practitioners from a non-medical background applied to attend the consultation after receiving an invitation, only to be placed on a waiting list and excluded just before the meeting without reason. This occurred across the board for many non-medical stakeholders.
No transparency: There is no publicly available list of attendees, no minutes, no record of what was said, how feedback was handled, or what level of representation different stakeholder groups had.
Post-event ambiguity: The only documentation shared was a brief slide presentation rather than a consultation report, which contained no stakeholder breakdowns, analysis, or evidence-based conclusions.
Admission of cover: In one communication, the NMC stated the roundtable was required “to avoid legal challenge,” suggesting the decision had already been made, and the consultation served as procedural cover.

Consequences: Black Markets, Business Closures, and Rising Risk

This abrupt change has triggered several damaging outcomes:

Black market sourcing is now on the rise as legitimate access to face-to-face prescribers becomes increasingly difficult.
Clients are being put at risk by being pushed toward unregulated providers.
Tax-paying aesthetic businesses, many of which are led by women, are facing financial strain, staff redundancies, or potential closure.
The NHS is now under greater pressure as medical professionals leave public roles for private practice, while legitimate private practitioners are forced out by bureaucratic red tape. This was evidenced by the national survey conducted by Faces Pharmacy.
Digital healthcare progress is being undermined, contradicting broader government initiatives to modernise healthcare delivery.

What the Nursing Times Revealed

Key details published by the Nursing Times further reinforced concerns, including:

The NMC clarified that this was not a formal consultation.
Remote prescribing is not yet entirely banned.
The NMC referred to face-to-face requirements in other sectors (e.g., the GMC), implying a compliance-based shift rather than an evidence-based one.
There was no clear explanation of how stakeholder input was used or weighted.
No explicit or urgent safety threat was cited to justify the change.

Why This Must Be Reviewed

This was not a lawful or inclusive consultation. It lacked:

Transparency
Balanced representation
Evidence and data-led policy formation
Public involvement
Stakeholder clarity

And the result has harmed:

Over half the aesthetics workforce
Client choice and access to safe, regulated services
Small business viability
Public trust in healthcare regulation

What Needs to Happen

We are now calling on the Professional Standards Authority and relevant government committees to:

Investigate the NMC’s conduct and process in this consultation.
Release the complete list of participants, minutes, and data collected.
Evaluate the role of JCCP lobbying in shaping this decision.
Reverse or review the policy change and call for a properly conducted, democratic consultation with full industry representation.

This policy has created more risks than it solves. It has ignored data, undermined fairness, and sidelined thousands of competent, insured, and trained professionals. Most importantly, it has left clients confused, unprotected, and pushed toward unsafe alternatives.

If we are serious about safety, fairness, and effective regulation, we must insist on better. The future of our industry and public trust depends on it.